Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...Term Loan Agreement • May 3rd, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
This TERM LOAN AGREEMENT, dated as of November 7, 2018, as amended by Amendment No. 1, dated as of May 3, 2019 is entered into among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the subsidiaries of the Borrower party hereto as Guarantors, the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, in its capacity as administrative agent and collateral agent for the Lenders (together with its permitted successors in such capacity, the “Agent”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 3rd, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Amendment No. 1 (this “Amendment”) to the Registration Rights Agreement, dated as of November 7, 2018 (the “2018 RRA”), by and among Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), and the parties identified on Schedule A thereto (each, a “Holder” and collectively, with such other Persons, if any, from time to time, that become a party thereto as holders of Registrable Securities, the “Holders”), is dated as of May 3, 2019. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the 2018 RRA.
